Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres
- 31 October 2008
- journal article
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 53 (22), 6591-6603
- https://doi.org/10.1088/0031-9155/53/22/019
Abstract
Selective internal radiotherapy (SIRT) using Yttrium-90 labeled resin microspheres is increasingly used for the radioembolization of unresectable liver metastases of colorectal cancer (CRC). The treatment can be simulated by scintigraphy with Tc(99m)-labeled macroaggregates of albumin (MAA). The aim of the study was to develop a predictive dosimetric model for SIRT and to validate it by correlating results with the metabolic treatment response. The simulation of the dosimetry was performed by mathematically converting all liver voxel MAA-SPECT uptake values to the absolute Y(90) activity. The voxel values were then converted to a simulated absorbed dose (Gy) using simple MIRD formalism. The metabolic response was defined as the change in total lesion glycolysis (TLG) on FDG-PET. A total of 39 metastatic liver lesions were studied in eight evaluable patients. The mean administered Y(90) activity was 1.69 GBq (range: 1.33-2.04 GBq). The median (95% CI) simulated absorbed dose (Gy) was 29 Gy (1–98 Gy) and 66 Gy(32–159 Gy) in the poor ( 50%),respectively [DOSAGE ERROR CORRECTED].Using a simple cut-off value of 1 for the MAA-tumor-to-normal uptake ratio, a significant metabolic response was predicted with a sensitivity of 89% (17/19), a specificity of 65% (13/20), a positive predictive value of 71% (17/24) and a negative predictive value of 87% (13/15). Integrated multimodality imaging allows prediction of metabolic response post radioembolization using Y(90)-resin microspheres, and should be used for patient selection.Keywords
This publication has 22 references indexed in Scilit:
- Radioembolization of Liver Metastases From Colorectal Cancer Using Yttrium-90 Microspheres With Concomitant Systemic Oxaliplatin, Fluorouracil, and Leucovorin ChemotherapyJournal of Clinical Oncology, 2007
- Multislice Computed Tomographic Angiography for Preinterventional Planning of Port Placement for Intra-Arterial Hepatic Infusion ChemotherapyJournal of Computer Assisted Tomography, 2007
- Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomographyNuclear Medicine Communications, 2007
- Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experienceInternational Journal of Radiation Oncology*Biology*Physics, 2006
- 90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135–150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic ImagingJournal of Vascular and Interventional Radiology, 2005
- Angiographic Considerations in Patients Undergoing Liver-directed TherapyJournal of Vascular and Interventional Radiology, 2005
- Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancerJournal of Surgical Oncology, 2004
- Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancerJournal of the American College of Surgeons, 2004
- Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Hepatic toxicity resulting from cancer treatmentInternational Journal of Radiation Oncology*Biology*Physics, 1995